Clinical Factors Associated with Asymptomatic Women Having Inconclusive Screening Mammography Results: Experiences from a Single Medical Center in Taiwan

Chun-Li Wang 1,2, Pi-Shan Hsu 2,3, Chia-Yen Lin 1,4,* and Shun-Fa Yang 1,5,*

Abstract: Screening mammography is used worldwide for the early detection of breast cancer in women experiencing no symptoms. The Breast Imaging Reporting and Database System (BI-RADS) is used to report mammographic findings. However, little is known about the clinical characteristics of Asian women with BI-RADS category 0, and we aimed to explore such characteristics in the context of Taiwan. This retrospective cross-sectional study was conducted using data from a single tertiary medical center. We examined the association of blood test data and estrogen exposure–related medical histories with BI-RADS reports from screening mammography of 4280 women between 1 January 2010 and 31 July 2019. The data of 4280 participants were evaluated, and they were categorized into BI-RADS category 0 (n = 413; 9.6%) and 1–5 (n = 3867; 90.4%) subgroups. In a multivariate analysis, breast surgery history and premenopausal status had a positive relationship with a category 0 status, with respective risk increases of 64% and 34% (p = 0.010 and 0.013). Hormone contraceptive use for ≥5 years was a negative independent predictor of having a category 0 status. In conclusion, breast surgery history and premenopausal status significantly increased the likelihood of individuals having incomplete mammographic findings, even when they were older than 45 years. Identifying related factors before screening mammography is helpful for clinical physicians to arrange more proper and alternative examination and obtain a definite diagnosis.

Keywords: mammography; BI-RADS 0; breast cancer screening; preventive medicine

1. Introduction

Breast cancer is the third leading cause of cancer death among women in Taiwan. In 2017, approximately 13,965 women were diagnosed as having the disease, and more than 2300 women died of it. The rate of new cases of female breast cancer was 117.8 per 100,000 women per year and the mortality rate was 20.1 per 100,000 women per year. [1]. The updated recommendations of the US Preventive Services Task Force in 2016 suggest biennial screening mammography for women aged 50 to 74 years (B Recommendation) [2].

In Taiwan, the Health Promotion Administration policy on cancer screening stipulates free mammography for breast cancer screening once every two years for women aged 45 to 69 years or those aged 40 to 44 years whose second-degree relatives have had breast cancer. Radiologists then assess the mammography findings according to the American College of Radiology’s Breast Imaging Reporting and Data System (BI-RADS) [3,4]. This allows them to clearly and consistently communicate results to the referring physician. However, mammography results are sometimes incomplete, meaning that additional
imaging evaluation (additional mammographic views or ultrasound) may be required; women with such incomplete results are considered to have a BI-RADS category of 0.

Several factors affect mammographic image quality. Technical factors include breast positioning, compression, optimum, sharpness, exposure, and contrast [5]. Clinical factors include a high mammographic breast density, menopausal status, and age [6]. Among such factors, high breast density, which reflects the extent of estrogen exposure, has the strongest association with several clinical characteristics and metabolic abnormalities, such as younger age, lower body mass index (BMI), premenopausal status, nulliparity, older age at first birth, family history of breast cancer [7], and high-density lipoprotein cholesterol (HDL-C), as a feature of metabolic syndrome [8].

Metabolic syndrome, a cluster of metabolic abnormalities including central obesity, dyslipidemia, insulin resistance, and hypertension, had been studied as a risk factor for several types of cancer [9–13]. Some prior studies indicated that women with metabolic syndrome were at elevated risk of developing breast cancer with worse prognosis, while others suggested the increased association was observed only in postmenopausal women, but not in premenopausal women [14]. Insulin resistance and chronic inflammation may be the underlying pathophysiology between metabolic syndrome and increased risk of breast cancer. However, the association between metabolic syndrome and breast density, as one of the major risk factors of breast cancer has been under-investigated. Whether a correlation between breast density and these other factors influences the interpretation of mammographic findings remains unclear.

This study investigated the association between factors, including patients’ clinical characteristics and metabolic abnormalities, especially metabolic syndrome components, and women having incomplete screening mammography examinations in Taiwan.

2. Materials and Methods

2.1. Study Population and Design

The present study was retrospective and cross-sectional in design. The data of women who received both periodic health examinations and routine screening mammography under the National Health Insurance program at Taichung Veterans General Hospital from 1 January 2010 to 31 July 2019 were analyzed. Patients with a history of any cancer and those whose mammography reports revealed BI-RADS category 6 were excluded. To investigate the correlation between patient characteristics and BI-RADS categories, the patients were further divided into two subgroups (BI-RADS category 0 and BI-RADS category 1–5). The study selection process is presented in Figure 1. The study protocol was approved by the Institutional Review Board (IRB) of Taichung Veterans General Hospital (IRB number CE19332B).
2.2. Data Collection

The Health Promotion Administration of Taiwan provides a preventive care service package for adults aged 40 years and older. The package includes medical history taking, recording of health behaviors (smoking status, alcohol consumption, and exercise habit), physical examinations, and laboratory examinations of blood and urine samples. BMI was calculated as body weight (kg)/height$^2$ (m$^2$). The laboratory examinations of blood samples consisted of measurements of fasting glucose, triglycerides (TGs), total cholesterol, HDL-C, alanine and aspartate aminotransferases, creatinine, and estimated glomerular filtration rate. A person was determined to have metabolic syndrome if they satisfied three of the following criteria [15]: measured systolic blood pressure of $\geq 130$ mmHg, diastolic blood pressure of $\geq 85$ mmHg, or antihypertensive medication use; waist circumference of $\geq 80$ cm; a TG level of $\geq 150$ mg/dL or antihyperlipidemic medication use; fasting glucose of $\geq 100$ mg/dL, oral antihyperglycemic drug use, or insulin injection administration; or HDL-C of $<50$ mg/dL.

We also compiled information on breast cancer risk factors, including history of a benign breast disease, menopausal status, history of breast surgery, history of breast cancer in second-degree relatives, age at menarche ($<12$, 12–13, or $\geq 14$ years), age at first live birth ($\leq 24$, 25–29, or $\geq 30$ years), number of abortions ($0$–$1$, $\geq 2$), parity (nulliparous, one birth, or two or more births), breastfeeding history, and use of hormonal contraceptives (never, $<5$ years, or $\geq 5$ years). Women who met one or more of the following conditions were considered in postmenopausal status: (1) self-report of natural menopause; (2) self-report of surgical menopause related to hysterectomy; or (3) self-report of surgical menopause related to bilateral oophorectomy. Those not meeting these conditions were considered in premenopausal status. Women who had lactated for at least 1 month were defined...
as having breastfed. The data were collected during interviews by trained staff before mammography.

2.3. Mammographic Assessment and Management Recommendations

As per the Health Promotion Administration policy on cancer screening, screening mammography is provided every 2 years for women aged 45 to 69 years and those aged 40 to 44 years whose second-degree relatives have had breast cancer. Mammography results were assessed with a single reading, and findings were recorded in a standardized lexicon by radiologists specializing in breast imaging by using the fourth or fifth edition of BI-RADS [3,4]. Individuals with normal, benign, or probably benign mammographic findings are interpreted as having BI-RADS category 1, 2 or 3. A BI-RADS category of 4 or 5 indicates a suspicion of malignancy, and category 6 indicates a biopsy-proven malignancy. Individuals with an incomplete assessment and for whom a practitioner has requested an additional diagnostic imaging survey are interpreted as having a BI-RADS category of 0.

On the basis of BI-RADS, the recommended management of positive mammography results in Taichung Veterans General Hospital is as follows [3,4]: Patients with a BI-RADS category of 2 have a 0% likelihood of malignancy and receive regular mammography screening every 2 years. Individuals with a BI-RADS category of 3 are associated with a low risk of breast cancer (>0% and ≤2% likelihood of malignancy), and repeated imaging in 6 months is recommended. A BI-RADS category of 4 or 5 necessitates an urgent pathologic evaluation with biopsy. A BI-RADS category of 0 indicates that additional diagnostic mammography or ultrasonography is required as soon as possible to provide a final assessment.

Breast composition, as known as breast density, is also categorized to four groups according to ACR-BIRADS classification. The new breast composition categories are as follows [4]: (A) the breasts are almost entirely fatty, (B) there are scattered areas of fibroglandular density, (C) the breasts are heterogeneously dense, which may obscure small masses, (D) the breasts are extremely dense, which lowers the sensitivity of mammography.

2.4. Statistical Analysis

Categorical data were expressed as numbers and percentages, whereas continuous variables were expressed as means ± standard deviations. Associations between all categorical variables and BI-RADS categories were determined through the chi-squared, Fisher’s exact, and the Mann–Whitney U test. We built our analysis model with a backward logistic regression model. Potential risk factors in the univariate logistic regression with p values less than 0.100 were entered into the multivariate model. A two-sided p value of <0.05 was considered statistically significant. All analyses were performed using SPSS version 22.0 (International Business Machines Corp., New York, NY, USA).

3. Results

In total, 4280 women received both periodic health examinations and routine screening mammography at our hospital from 1 January 2010 to 31 July 2019. The average age of the participants was 56 years (range, 40–69) and 413 (9.6%) and 3867 (90.4%) patients were in the BI-RADS category 0 and 1–5 subgroups, respectively (Figure 1). Table 1 presents the clinical, reproductive, and laboratory parameters of those in the BI-RADS category subgroups.
Table 1. Clinical characteristics and component of metabolic syndrome of participants by BI-RADS category.

| BI-RADS Category 1–5 (n = 3867) | BI-RADS Category 0 (n = 413) | p Value |
|---------------------------------|-------------------------------|---------|
| Age 56.92 ± 7.20               | 56.30 ± 7.51                 | 0.124   |
| Metabolic syndrome              |                               | 0.978   |
| No                              | 2985 (77.19%)                |         |
| Yes                             | 882 (22.81%)                 |         |
| WC ≥ 80 cm (n = 4270)           | 1571 (40.72%)                | 1.000   |
| TG ≥ 150 mg/dL (n = 4278)       | 3745 (96.90%)                | 0.942   |
| HDL < 50 mg/dL (n = 4270)       | 736 (19.08%)                 |         |
| Fasting glucose ≥ 100           |                               | 1.000   |
| mg/dL/diabetes (n = 4278)       | 3836 (99.25%)                | 0.763   |
| SBP ≥ 130 mmHg/DBP ≥ 85         | 3860 (99.87%)                | 1.000   |
| BMI (n = 4276)                  |                               |         |
| <18.5                           | 110 (2.85%)                  |         |
| 18.5–23.9                       | 2040 (52.80%)                |         |
| ≥24                             | 1714 (44.36%)                |         |
| Current smoker                  | 77 (1.99%)                   | 0.534   |
| Alcohol drinking                | 379 (9.80%)                  |         |
| Habit of exercise               |                               | 0.368   |
| No                              | 1475 (38.14%)                |         |
| <2.5 hr/week                    | 1383 (35.76%)                |         |
| ≥2.5 hr/week                    | 1009 (26.09%)                |         |
| History of benign breast disease| 714 (18.46%)                 | 0.533   |
| Menopause status                |                               | 0.010   |
| Premenopausal                   | 822 (21.26%)                 |         |
| Postmenopausal                  | 3045 (78.74%)                |         |
| History of breast surgery       | 210 (5.43%)                  | 0.016   |
| Family history of breast cancer | 278 (7.19%)                  |         |
| Age at menarche, years          |                               | 0.500   |
| ≤12                             | 104 (2.69%)                  |         |
| 12–13                           | 1342 (34.70%)                |         |
| ≥14                             | 2421 (62.61%)                |         |
| Age at first live birth, years (n = 3896) |                       | 0.428   |
| ≤24                             | 1168 (33.20%)                |         |
| 25–29                           | 1680 (47.75%)                |         |
| ≥30                             | 670 (19.04%)                 |         |
| Abortion                        |                               | 0.039   |
| 0–1                             | 3008 (77.79%)                |         |
| ≥2                              | 859 (22.21%)                 |         |
| Parity                          |                               | 0.708   |
| Nulliparous                     | 347 (8.97%)                  |         |
| 1                               | 419 (10.84%)                 |         |
| ≥2                              | 3101 (80.19%)                |         |
| Breast feeding                  | 2011 (52.00%)                |         |
| Use of hormonal contraceptives  |                               | 0.048   |
| No                              | 3095 (80.04%)                |         |
| <5 years                        | 600 (15.52%)                 |         |
| ≥5 years                        | 172 (4.45%)                  |         |
| Breast composition BI-RADS      |                               | 0.182   |
| A                               | 23 (0.60%)                   |         |
| B                               | 138 (3.57%)                  |         |
| C                               | 3324 (86.00%)                |         |
| D                               | 380 (9.83%)                  |         |

Chi-Square test. * Fisher’s Exact test. Mann–Whitney U test. * p < 0.05. Values were expressed as numbers and percentages (or mean and SD).

The proportion of patients with premenopausal status was higher in the BI-RADS category 0 subgroup than in the category 1–5 subgroup (26.8% vs. 21.26%, respectively;
The incidence of breast surgery history in the two subgroups was 8.47% and 5.43%, respectively ($p = 0.016$). The proportion of individuals who underwent <2 abortions was higher in the BI-RADS category 0 subgroup than in the category 1–5 subgroup (82.32% vs. 77.79%; $p = 0.039$). A significantly smaller proportion of individuals in the BI-RADS category 0 group had used hormonal contraceptives for more than five years (1.94% vs. 4.45%; $p = 0.048$). Overall, most patients had high breast density category (BI-RADS C-D) in both subgroups, but no significant difference between the two groups was noted.

Adjustment for baseline covariates (Table 2) revealed that the BI-RADS category 0 subgroup had a significantly lower association with hormonal contraceptive usage (OR = 0.91, 95% CI = 0.83–0.99, $p = 0.034$) and use of hormonal contraceptives for $\geq 5$ years (OR = 0.42, 95% CI = 0.20–0.86, $p = 0.018$). Compared with the other subgroup, those in BI-RADS category 0 subgroup had a 33% ($p = 0.034$), 61% ($p = 0.012$), and 36% ($p = 0.009$) higher association with undergoing <2 abortions, having a history of breast surgery, and having premenopausal status, respectively. Based on multivariate analysis (Table 2), hormonal contraceptive use for $\geq 5$ years (OR = 0.42; 95% CI, 0.21–0.87, $p = 0.019$) was a negative independent predictor of having an incomplete mammographic assessment. By contrast, a positive relationship was observed between BI-RADS category 0 and individuals having a history of breast surgery or premenopausal status.

### Table 2. Univariate and multivariate logistic regression analysis: independent variables assessed incomplete mammographic evaluation (BI-RADS category 0).

| Metabolic syndrome | Num | OR  | 95% CI        | $p$ Value | OR  | 95% CI        | $p$ Value |
|--------------------|-----|-----|---------------|-----------|-----|---------------|-----------|
| No                 | 318 | ref.|               |           |     |               |           |
| Yes                | 95  | 1.01| (0.79–1.29)   | 0.929     |     |               |           |
| Menopause status   |     |     |               |           |     |               |           |
| Post               | 302 | ref.|               |           |     |               |           |
| Pre                | 111 | 1.36| (1.08–1.71)   | 0.009 **  | 1.34| (1.06–1.69)   | 0.013 *   |
| Abortion ≥2        | 73  | ref.|               |           |     |               |           |
| 0–1                | 340 | 1.33| (1.02–1.73)   | 0.034 *   |     |               |           |
| History of breast surgery | |     |               |           |     |               |           |
| No                 | 378 | ref.|               |           |     |               |           |
| Yes                | 35  | 1.61| (1.11–2.34)   | 0.012 *   | 1.64| (1.13–2.39)   | 0.010 *   |
| Use of hormonal contraceptives | |     |               |           |     |               |           |
| No                 | 343 | ref.|               |           |     |               |           |
| <5 years           | 62  | 0.93| (0.70–1.24)   | 0.629     | 0.95| (0.71–1.26)   | 0.719     |
| ≥5 years           | 8   | 0.42| (0.20–0.86)   | 0.018 *   | 0.42| (0.21–0.87)   | 0.019 *   |
| Breast composition BI–RADS | |     |               |           |     |               |           |
| A                  | 0   | 0.00| (0.00–0.00)   | 0.998     |     |               |           |
| B                  | 9   | 0.64| (0.30–1.35)   | 0.236     |     |               |           |
| C                  | 365 | 1.07| (0.76–1.51)   | 0.703     |     |               |           |
| D                  | 39  | ref.|               |           |     |               |           |

Logistic regression. * $p < 0.05$, ** $p < 0.01$. Abbreviation: Num, number; OR, odds ratio; CI, confidence interval. All available risk factors were entered into the univariate analysis, but only potential ones ($p$-Value < 0.100) were listed.

### 4. Discussion

Despite the developing techniques of medical treatment of breast cancer, health examinations are a very important part of preventive medical care. Mammography is an established screening test for breast cancer, but the problem of incomplete assessment needs to be solved. The present study identified several factors leading to incomplete mammography findings. A breast surgery history and premenopausal status significantly increased the risk of individuals having incomplete results. Women with these features undergoing breast cancer screening may consider receiving initial ultrasound assessment instead.
Surgical interventions for the breast may be for cosmetic or health reasons, but most lead to breast tissue reposition and scar formation [16]. On mammography, scar tissue appears as an architectural distortion, tissue asymmetry, or spiculated opacity, affecting the interpretation of radiological findings. Mammography is inferior to ultrasonography in terms of distinguishing such postsurgical breast changes [17]; uncertain or false image interpretations are common. Therefore, women with a history of breast surgery are not suitable candidates to receive mammography as a breast cancer screening tool.

The association between mammographic sensitivity related to noncalcified lesions and BI-RADS breast density category is well known [3,4]. Premenopausal women, owing to their greater estrogen exposure, tend to have more fibroglandular breast tissue components and denser breasts; these factors reduce the accuracy and sensitivity of mammography [18–22]. The correlation between premenopausal status and having a BI-RADS category of 0 is in the same direction as the association with this category and breast density. High breast density, incomplete assessment, and the elevated breast cancer risk are interrelated. Beside premenopausal status, clinical factors such as increasing height, higher levels of education, and later first birth were associated with higher mammography density [23], and the change of mammography density in follow-up screening study was associated with breast cancer risk, reported recently in East Asian women [24]. Therefore, the national policy of only taking age and familial breast cancer history into consideration as criteria for women to undergo breast cancer screening in Taiwan may need to put more emphasis on the other clinical factors and arrange alternative and effective examination.

Exogenous hormone exposure is related to changes in breast density [25–29]. In most related studies, hormonal contraceptives, including those containing estrogen and progestin, increased individuals' breast density on mammographic imaging. Our findings led to a different conclusion on the influence of hormonal contraceptive exposure. One previous study revealed that the use of estrogen alone for one year did not affect the mean mammographic breast density of women, but greater density was associated with the use of estrogen–progestin combination therapy [30]. Another study revealed an association of hormone exposure with mammographic density; among breast cancer–free individuals, oral contraceptive users had had a lower breast density than nonusers [29]. Other clinical factors are associated with the effects of exogenous hormone supplements on breast density changes, but a consensus has not been reached. Further details on oral contraceptive use (e.g., type) were not obtained in our study; further investigation of these factors may be warranted.

Regular health examinations slow down the transformation from preclinical phase to clinical phase, with a consequent reduction in mortality. A proper screening test must be acceptable to most of the population, simple, conveniently operable, non-invasive, low danger, relatively low cost, and most important, must have a high sensitivity and specificity [31,32]. Mammography for breast cancer screening meets the criteria for a screening tool, and the reported sensitivity and specificity in Asian population were 77.0% and 91.4% [33]. As long as screening combined an adjunctive ultrasonography in specific women, the sensitivity and detection rate of early cancers increased [33–36]. Using an accurate screening tool for an appropriate population provides precise healthcare.

Though many studies have concluded that high breast density disturbs mammography assessment, more than 90% of the patients who underwent screening mammography in this study had complete finding, categorized as BI-RADS 1–5. This showed that the screening mammography examination in Taichung Veteran General Hospital could give enough assurance and confidence to the healthy women, and the results achieved superior performance compared to other developed countries [37]. This may result from the fact that Taichung Veteran General Hospital, as a medical center, has high resolution of image examination and high quality of reporting system by breast image radiologists. Breast density did not become a distracting factor.

The strengths of this study are as follows: first, the study contributes to the literature by examining the factors related to incomplete mammography screening, serving to remind
clinicians to use the most suitable and sensitive tools for breast cancer screening. Second, our study had a large sample size and a long recruitment period, and all patients had comprehensive blood and reproductive data. Nevertheless, this study has limitations. This was a retrospective single-center study, limiting the generalizability of our results. Furthermore, subsequent definite diagnosis and prognosis after incomplete mammography, which are among the most vital concerns for clinicians, were not traced in our study. Finally, as mentioned, owing to different breast density changes that can result from different hormone supplement regimens and frequencies, more details on oral contraceptive treatments should be obtained.

5. Conclusions

The completion of screening mammography was determined mostly by patients’ medical history and estrogen exposure background rather than by metabolic syndrome–related factors. Our results indicate that breast surgery history and premenopausal status are independently associated with individuals having a BI-RADS category of 0. Identifying related factors and providing timely health education are crucial so that additional examinations can be arranged to obtain a definite diagnosis as early as possible.

Author Contributions: Conceptualization, C.-L.W., P.-S.H. and C.-Y.L.; data curation, C.-L.W., P.-S.H. and C.-Y.L.; writing—original draft preparation, C.-L.W., C.-Y.L. and S.-F.Y.; writing—review and editing, C.-L.W., C.-Y.L. and S.-F.Y.; All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board (IRB) of Taichung Veterans General Hospital (IRB number CE19332B).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The dataset generated and analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ministry of Health and Welfare. Causes of Deaths Statistics. 2019. Available online: https://www.mohw.gov.tw/np-128-2.html (accessed on 14 September 2020).
2. US Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2016, 164, 279–296. [CrossRef] [PubMed]
3. D’Orsi, C.J.; Sickles, E.A.; Mendelson, E.B.; Morris, E.A. ACR BI-RADS Atlas, Breast Imaging Reporting and Data System; American College of Radiology: Reston, VA, USA, 2003.
4. D’Orsi, C.J.; Sickles, E.A.; Mendelson, E.B.; Morris, E.A. ACR BI-RADS Atlas, Breast Imaging Reporting and Data System; American College of Radiology: Reston, VA, USA, 2013.
5. Eklund, G.W.; Cardenosa, G.; Parsons, W. Assessing adequacy of mammographic image quality. Radiology 1994, 190, 297–307. [CrossRef] [PubMed]
6. Justice, T.D.; Stiff, J.H.; Myers, J.A.; Milam, M.R. Prediction of Incomplete Screening Mammograms Based on Age and Race. J. Am. Board Fam. Med. 2012, 25, 128–130. [CrossRef] [PubMed]
7. Boyd, N.F.; Lockwood, G.A.; Byng, J.W.; Little, L.E.; Yaffe, M.J.; Tritchler, D.L. The relationship of anthropometric measures to radio-logical features of the breast in premenopausal women. Br. J. Cancer 1998, 78, 1233–1238. [CrossRef]
8. Tehranifar, P.; Protacio, A.; Schmitt, K.M.; Desperito, E.; Oskar, S.; Potter, A.J.; Engmann, N.J.; Terry, M.B. The metabolic syndrome and mammographic breast density in a racially diverse and predominantly immigrant sample of women. Cancer Causes Control 2015, 26, 1393–1403. [CrossRef] [PubMed]
9. Lund Håheim, L; Wilsieff, T.F.; Holme, I.; Nafstad, P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am. J. Epidemiol. 2006, 64, 769–774. [CrossRef] [PubMed]
10. Laukkanen, J.A.; Laaksonen, D.E.; Niskanen, L.; Pukkala, E.; Hakkarainen, A.; Salonen, J.T. Metabolic syndrome and the risk of prostate cancer in Finnish men: A population-based study. Cancer Epidemiol. Biomark. Prev. 2004, 13, 1646–1650.

11. Ahmed, R.L.; Schumit, K.H.; Anderson, K.E.; Rosamond, W.D.; Folsom, A.R. The metabolic syndrome and risk of incident colorectal cancer. Cancer 2006, 107, 28–36. [CrossRef]

12. Kim, J.H.; Lim, Y.J.; Kim, Y.-H.; Sung, I.-K.; Shim, S.G.; Oh, S.-O.; Park, S.-S.; Yang, S.; Son, H.J.; Rhee, P.-L.; et al. Is Metabolic Syndrome A Risk Factor for Colorectal Adenoma? Cancer Epidemiol. Biomark. Prev. 2007, 16, 1543–1546. [CrossRef]

13. Kabat, G.C.; Kim, M.; Chlebowski, R.T.; Khandekar, J.; Ko, M.G.; McTiernan, A.; Neuhausser, M.L.; Parker, D.R.; Shikany, J.M.; Stefanick, M.L.; et al. A Longitudinal Study of the Metabolic Syndrome and Risk of Postmenopausal Breast Cancer. Cancer Epidemiol. Biomark. Prev. 2009, 18, 2046–2055. [CrossRef]

14. Guo, M.; Liu, T.; Li, P.; Wang, T.; Zeng, C.; Yang, M.; Li, G.; Han, J.; Wu, W.; Zhang, R. Association Between Metabolic Syndrome and Breast Cancer Risk: An Updated Meta-Analysis of Follow-Up Studies. Front. Oncol. 2019, 9, 1290. [CrossRef] [PubMed]

15. Grundy, S.M.; Cleeman, J.I.; Merz, C.N.; Brewer, H.B., Jr.; Clark, L.T.; Hunninghake, D.B.; Pasternak, R.C.; Smith, S.C.; Stone, N.J.; Coordinating Committee of the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110, 227–239. [CrossRef] [PubMed]

16. Ramani, S.K.; Rastogi, A.; Mahajan, A.; Nair, N.; Shet, T.; Thakur, M.H. Imaging of the treated breast post breast conservation surgery/onsoplasty: Pictorial review. World J. Radiol. 2017, 9, 321–329. [CrossRef]

17. Esen, G.; Olgun, D.C. Ultrasonography of the Postsurgical Breast Including Implants. Ultrasound Clin. 2008, 3, 295–329. [CrossRef]

18. Devolli-Disha, E.; Manxhuka-Kërliu, S.; Ymeri, H.; Kutflovci, A. Comparative Accuracy of Mammography and Ultrason in Women with Breast Symptoms According to Age and Breast Density. Bosn. J. Basic Med. Sci. 2009, 9, 131–136. [CrossRef] [PubMed]

19. Houssami, N.; Irwig, L.; Simpson, J.M.; McKessar, M.; Blome, S.; Noakes, J. The Influence of Knowledge of Mammography Findings on the Accuracy of Breast Ultrasound in Symptomatic Women. Breast J. 2005, 11, 167–172. [CrossRef] [PubMed]

20. Saarennmaa, I.; Salminen, T.; Geiger, U.; Heikkinen, P.; Hyytärinen, S.; Isoa, J.; Kataja, V.; Kokko, M.-L.; Kokko, R.; Kumpulainen, E.; et al. The effect of age and density of the breast on the senictivity of breast cancer diagnosis by mammography and ultrasonography. Breast Cancer Res. Treat. 2006, 67, 117–123. [CrossRef] [PubMed]

21. Sibbering, D.; Burrell, H.; Evans, A.; Yeoman, L.; Wilson, A.; Robertson, J.; Blarney, R. Mammographic sensitivity in women under 50 years presenting symptomatically with breast cancer. Breast 1995, 4, 127–129. [CrossRef]

22. Ciatto, S.; Del Turco, M.R.; Catarzi, S.; Morrone, D. The contribution of ultrasonography to the differential diagnosis of breast cancer. Neoplasia 1994, 41, 341–345.

23. Sung, H.; Ren, J.; Li, J.; Pfeiffer, R.M.; Wang, Y.; Guida, J.L.; Fang, Y.; Shi, J.; Zhang, K.; Li, N.; et al. Breast cancer risk factors and mammographic density among high-risk women in urban China. NPJ Breast Cancer 2018, 4, 1–12. [CrossRef] [PubMed]

24. Kim, S.; Park, B. Association between changes in mammographic density category and the risk of breast cancer: A nationwide cohort study in East-Asian women. Int. J. Cancer 2021, 148, 2674–2684. [CrossRef] [PubMed]

25. McTiernan, A.; Martin, C.F.; Peck, J.D.; Aragaki, A.K.; Chlebowski, R.T.; Pisano, E.D.; Wang, C.Y.; Brunner, R.L.; Johnson, K.C.; Manson, J.E.; et al. Women’s Health Initiative Mammographic Density Study Investigators. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women’s Health Initiative randomized trial. J. Natl. Cancer Inst. 2005, 97, 1366–1376. [CrossRef]

26. Topal, N.B.; Ayhan, S.; Topal, U.; Bilgin, T. Effects of hormone replacement therapy regimens on mammographic breast density: The role of progestins. J. Obstet. Gynaecol. Res. 2006, 32, 305–308. [CrossRef] [PubMed]

27. Greendale, G.A.; Rebourssin, B.A.; Sie, A.; Singh, H.R.; Olson, L.K.; Gatewood, O.; Bassett, L.W.; Wasilauskaas, C.; Bush, T. Effects of estrogen and estrogen-progestin on mammographic parenchymal density: Postmenopausal Estrogen/Progestin Intervention (PEPI) Investigators. Ann. Intern. Med. 1999, 130, 262–269. [CrossRef] [PubMed]

28. Spicer, D.V.; Ursin, G.; Parisky, Y.R.; Pearce, J.G.; Shoupe, D.; Pike, A.; Pike, M.C. Changes in mammographic densities induced by a hor-monal contraceptive designed to reduce breast cancer risk. J. Natl. Cancer Inst. 1994, 86, 431–436. [CrossRef]

29. Boyd, N.F.; Melnhouch, O.; Martin, L.J.; Hislop, G.; Chiarelli, A.M.; Yaffe, M.J.; Minkin, S. Mammographic Density, Response to Hormones, and Breast Cancer Risk. J. Clin. Oncol. 2011, 29, 2985–2992. [CrossRef]

30. Greendale, G.A.; Rebourssin, B.; Slone, S.; Wasilauskaas, C.; Pike, M.C.; Ursin, G. Postmenopausal hormone therapy and change in mammographic density. J. Natl. Cancer Inst. 2005, 97, 30–37. [CrossRef]

31. Marshall, K.G. Prevention. How much harm? How much benefit? 2. Ten potential pitfalls in determining the clinical signifi-cance of benefits. CMAJ 1996, 154, 1837–1843.

32. Cole, P.; Morrison, A.S. Basic Issues in Population Screening for Cancer. J. Natl. Cancer Inst. 1980, 64, 1263–1272. [CrossRef]

33. Ohuchii, N.; Suzuki, A.; Sobue, T.; Kawai, M.; Yamamoto, S.; Zheng, Y.F.; Shiono, Y.N.; Saito, H.; Kuriyama, S.; Tohno, E.; et al. Sensitivity and specificity of mammography and ad-junctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): A ran-domised controlled trial. Lancet 2016, 387, 341–348. [CrossRef]
34. Kolb, T.M.; Lichy, J.; Newhouse, J.H. Comparison of the Performance of Screening Mammography, Physical Examination, and Breast US and Evaluation of Factors that Influence Them: An Analysis of 27,825 Patient Evaluations. *Radiology* **2002**, *225*, 165–175. [CrossRef] [PubMed]

35. Corsetti, V.; Houssami, N.; Ghirardi, M.; Ferrari, A.; Speziani, M.; Bellarosa, S.; Remida, G.; Gasparotti, C.; Galligioni, E.; Ciatto, S. Evidence of the effect of adjunct ultrasound screening in women with mammography-negative dense breasts: Interval breast cancers at 1 year follow-up. *Eur. J. Cancer* **2011**, *47*, 1021–1026. [CrossRef] [PubMed]

36. Corsetti, V.; Houssami, N.; Ferrari, A.; Ghirardi, M.; Bellarosa, S.; Angelini, O.; Bani, C.; Sardo, P.; Remida, G.; Galligioni, E.; et al. Breast screening with ultrasound in women with mammography-negative dense breasts: Evidence on incremental cancer detection and false positives, and associated cost. *Eur. J. Cancer* **2008**, *44*, 539–544. [CrossRef]

37. Sirous, M.; Shahnani, P.S.; Sirous, A. Investigation of Frequency Distribution of Breast Imaging Reporting and Data System (BI-RADS) Classification and Epidemiological Factors Related to Breast Cancer in Iran: A 7-year Study (2010–2016). *Adv. Biomed. Res.* **2018**, *7*, 56. [PubMed]